1 Department of Radiology, The Ohio State University Wexner Medical Center , Columbus, Ohio.
2 Departments of Radiology and Biostatistics and Bioinformatics, Carl E. Ravin Advanced Imaging Laboratories, Duke University Medical Center , Durham, North Carolina.
Thyroid. 2018 Mar;28(3):295-300. doi: 10.1089/thy.2017.0526. Epub 2018 Feb 22.
In many risk-stratification systems, the decision to biopsy thyroid nodules is determined by their sonographic features and size. Nevertheless, even low-suspicion nodules are often biopsied at small size thresholds because it is assumed that larger malignant nodules are associated with poorer outcomes. The aim of this study was to quantify the effect of thyroid cancer tumor size on survival and risk of T4 stage, nodal disease, and distant metastases.
The Surveillance, Epidemiology, and End Results 18 database was queried to obtain tumor size, staging information, and survival data for cases of differentiated thyroid cancer (DTC) and non-DTC reported between 2004 and 2014. Observed probabilities of tumor extent at diagnosis, including regional nodal disease and distant metastases, as a function of size and tumor histology were estimated for thyroid cancers measuring between 1 and 150 mm. A multivariate Cox regression model was used to describe all-cause mortality as a function of patient and tumor characteristics, and the functional dependence of mortality on size was computed.
A total of 112,128 patients were analyzed, with 67% having thyroid cancers ≥1 cm, and 29% ≥ 2.5 cm. For DTC tumors <4 cm, the risk of local invasion, nodal metastases, or distant metastases was low, and there was no size threshold associated with a sharp rise in adverse outcomes. For DTC tumors <4 cm, the probability of distant metastases was <3%. Older age, male sex, non-DTC histology, T4 stage, and regional and distant metastatic disease increased the all-cause mortality rate. Tumor size did not increase the mortality rate above baseline until tumors were >2.5 cm.
Increasing tumor size does not affect survival until a threshold of 2.5 cm. Since the dimension of nodules on ultrasound has been shown to be larger than their size at gross pathology, these findings suggest that recommended size thresholds to biopsy low-suspicion thyroid nodules can be increased.
在许多风险分层系统中,对甲状腺结节进行活检的决定取决于其超声特征和大小。然而,即使是低可疑性结节,也常常在小的大小阈值下进行活检,因为人们认为较大的恶性结节与较差的预后相关。本研究旨在量化甲状腺癌肿瘤大小对生存以及 T4 期、淋巴结疾病和远处转移风险的影响。
查询监测、流行病学和最终结果 18 数据库,以获取 2004 年至 2014 年间报告的分化型甲状腺癌(DTC)和非 DTC 病例的肿瘤大小、分期信息和生存数据。对于测量大小在 1 至 150mm 之间的甲状腺癌,估计了肿瘤大小和肿瘤组织学与诊断时的局部淋巴结疾病和远处转移范围相关的概率。使用多变量 Cox 回归模型描述了全因死亡率与患者和肿瘤特征的关系,并计算了死亡率对大小的函数依赖性。
共分析了 112128 例患者,其中 67%的患者甲状腺癌大小≥1cm,29%的患者甲状腺癌大小≥2.5cm。对于<4cm 的 DTC 肿瘤,局部侵犯、淋巴结转移或远处转移的风险较低,并且没有与不良预后急剧上升相关的大小阈值。对于<4cm 的 DTC 肿瘤,远处转移的概率<3%。年龄较大、男性、非 DTC 组织学、T4 期以及局部和远处转移疾病增加了全因死亡率。直到肿瘤大小>2.5cm 时,肿瘤大小才会增加死亡率超过基线。
直到肿瘤大小达到 2.5cm 时,肿瘤大小才会影响生存。由于超声上结节的尺寸已经显示出比大体病理上的尺寸更大,这些发现表明可以增加推荐用于活检低可疑性甲状腺结节的大小阈值。